| DC Field | Value | Language |
|---|
| dc.contributor.author | Gudyrev, O. S. | - |
| dc.contributor.author | Andronova, T. M. | - |
| dc.contributor.author | Nesterova, E. I. | - |
| dc.date.accessioned | 2022-04-25T10:20:19Z | - |
| dc.date.available | 2022-04-25T10:20:19Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Gudyrev, O.S. The results of the study of the carcinogenic properties of glucosaminylmuramyldipeptide GMDP in chronic experiments in mice and rats / O.S. Gudyrev, T.M. Andronova, E.I. Nesterova // Research Results in Pharmacology. - 2018. - Vol. 4, № 4.- P. 97-106. - Doi: 10.3897/rrpharmacology.4.32191. - Refer.: p. 106. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46333 | - |
| dc.description.abstract | The drug Licopid (GMDP, glucosaminylmuramyldipeptide) is intended for complex therapy of conditions accompanied by secondary immunodeficiencies. The objective of this study was to investigate the carcinogenicity of GMDP (Licopid®) in chronic animal experiments | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | GMDP | ru |
| dc.subject | glucosaminylmuramyldipeptide | ru |
| dc.subject | Licopid® | ru |
| dc.subject | carcinogenicity | ru |
| dc.title | The results of the study of the carcinogenic properties of glucosaminylmuramyldipeptide GMDP in chronic experiments in mice and rats | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 4, № 4
|
